Pregnancy and thyroid cancer: ultrasound study of foetal thyroid.
Thyroid cancer is the most common endocrine malignancy, more frequently diagnosed in young women during childbearing age and approximately 10% of all thyroid cancers are diagnosed during pregnancy or in the early post-partum period. Thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar cancer. Pregnancy after treatment of thyroid carcinoma requires both maternal and foetal controls. Of utmost importance is to ensure adequate maintenance of maternal levels of levothyroxine, needed by both the foetal central nervous system for its normal maturation and the mother to avoid possible recurrence or spread of the disease. In the present investigation, to confirm normal foetal growth and foetal thyroid development, an ultrasound study of the foetal thyroid was performed in 40 full term pregnancies in 32 women receiving levothyroxine treatment for previously treated thyroid cancer. In patients undergoing either suppressive or substitutive levothyroxine treatment, foetal thyroid growth was noted to be normal in all the cases, newborn thyroid status was always normal, and the incidence of maternal morbidity was not influenced. In the present study group, pregnancy does not appear to compromise mother's disease-free interval, nor to be compromised by thyroid cancer treatment. Results of the present study confirm that regular adjustment of levothyroxine treatment is of utmost importance for both maternal and foetal well-being and that foetal thyroid ultrasound study may add useful and reassuring data about child well-being.
Zamperini
P
P
Head & Neck Surgery Division, Thyroid Cancer Unit, European Institute of Oncology, Milan, Italy.
Gibelli
B
B
Gilardi
D
D
Tradati
N
N
Chiesa
F
F
D005260:Female; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy; D011256:Pregnancy Outcome; D013961:Thyroid Gland / Q000000981:diagnostic imaging* / Q000196:embryology*; D013964:Thyroid Neoplasms / Q000628:therapy; D016216:Ultrasonography, Prenatal
Best Pract Res Clin Endocrinol Metab. 2004 Jun;18(2):225-48
15157838
Obstet Gynecol. 2003 Aug;102(2):232-41
12907094
N Engl J Med. 1994 Oct 20;331(16):1072-8
8090169
Eur J Endocrinol. 1999 May;140(5):404-6
10229904
N Engl J Med. 2004 Jul 15;351(3):241-9
15254282
Obstet Gynecol Surv. 1989 Nov;44(11):774-9
2677860
J Clin Endocrinol Metab. 1997 Sep;82(9):2862-6
9284711
Laryngoscope. 2007 Oct;117(10):1777-81
17690608
Curr Opin Obstet Gynecol. 2005 Apr;17(2):123-7
15758602
Oncologist. 2008 May;13(5):539-47
18515739
J Surg Oncol. 1994 Jan;55(1):61-4
8289456
Am J Epidemiol. 2005 Jun 1;161(11):1056-65
15901626
Fertil Steril. 2000 Dec;74(6):1063-70
11119728
J Reprod Med. 2007 May;52(5):416-8
17583242
Minerva Endocrinol. 2003 Sep;28(3):233-45
14605605
Gynecol Endocrinol. 2002 Dec;16(6):427-30
12626028
Endocrinol Metab Clin North Am. 1995 Mar;24(1):41-71
7781627
Endocrinol Metab Clin North Am. 2006 Mar;35(1):117-36, vii
16310645
J Nucl Med. 1996 Apr;37(4):606-12
8691249
Thyroid. 1999 Jul;9(7):667-70
10447012
Obstet Gynecol Clin North Am. 2004 Dec;31(4):893-905, xi
15550341
J Nucl Med. 1995 Jan;36(1):21-7
7799075
Arq Bras Endocrinol Metabol. 2006 Oct;50(5):930-3
17160219
Clin Obstet Gynecol. 1997 Mar;40(1):81-9
9103951
N Engl J Med. 1999 Aug 19;341(8):549-55
10451459
Int J Gynaecol Obstet. 2005 Oct;91(1):15-20
16085061
Nucl Med Commun. 2000 Feb;21(2):127-8
10758605
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):449-55
16095849
Treat Endocrinol. 2005;4(1):31-41
15649099
J Surg Oncol. 2005 Sep 1;91(3):199-203
16118775
Nat Clin Pract Endocrinol Metab. 2007 Jun;3(6):470-8
17515891
Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):76-81
15167041
Growth Horm IGF Res. 2003 Aug;13 Suppl A:S45-54
12914727
Thyroid. 1994 Winter;4(4):433-5
7711507
Thyroid. 2007 Jun;17(6):543-7
17614775